North Brunswick, NJ, July 23, 2008: ProFACT Proteomics, Inc. is to be awarded an Incubator Seed Fund Grant as announced by the New Jersey Commission on Science and Technology on June 24, 2008. The funds will support development and filing of up to six new patents enhancing its platform tools in drug target and biomarker discovery.
About ProFACT Proteomics, Inc.
ProFACT Proteomics, Inc. is a privately held early-stage corporation which applies its enabling proprietary Proteomics technology, for development of therapeutics, diagnostics and personalized medicine, principally for cancer. Through partnership and service agreements, ProFACT participates in 4 key platform areas: SeraFILE™, for reduction of protein complexity and sub-proteome creation; Rational Proteome Prospecting™, to enrich and isolate functional activity; Conformerics™, to generate drug screening assays based on enzyme sub-states or conformers; and Rational Genome to Proteome Prospecting™, for prospecting into protein expression based on gene expression data.
